ECOR
electroCore, Inc. [ECOR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ECOR Stock Summary
Top 10 Correlated ETFs
ECOR
Top 10 Correlated Stocks
ECOR
In the News
ECOR Financial details
Company Rating
-
Market Cap
34.46M
Income
-18.83M
Revenue
16.03M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
68
Optionable
No
Shortable
Yes
Earnings
01 May 2024
P/E
-1.73
Forward P/E
-
PEG
0.72
P/S
2.68
P/B
3.23
P/C
-
P/FCF
-2.3
Quick Ratio
1.65
Current Ratio
2.1
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.56
EPS next Y
-
EPS next Q
-
EPS this Y
-27.08%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-31.72%
Revenue last 5Y
46.32%
Revenue Q/Q
15.15%
EPS Q/Q
-10.29%
-
-
-
-
SMA20
1.87%
SMA50
-18.9%
SMA100
-65.89%
Inst Own
-
Inst Trans
-
ROA
-102%
ROE
-175%
ROC
-1.83%
Gross Margin
83%
Oper. Margin
-158%
Profit Margin
-154%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.829-8.08
52W High
-36.38%
52W Low
+69.67%
RSI
41.53
Rel Volume
5
Avg Volume
13.38K
Volume
66.96K
Perf Week
-4.5%
Perf Month
-32.76%
Perf Quarter
-67.1%
Perf Half Y
-64.9%
-
-
-
-
Beta
0.933
-
-
Volatility
0.22%, 0.65%
Prev Close
-5.21%
Price
5.09
Change
-9.11%
Company Profile
- Volume Average 13.38K
- Market Capitalization 34.46M
- Employee 68
- CEO Mr. Daniel S. Goldberger
- Headquarters Rockaway,NJ,US
- IPO Date 2018-06-22
-
Website
https://www.electrocore.com 
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
